– Cancer and Innate Immunity
– Developmental and Cancer Biology
– Cancer Drug Discovery
– Genetics and Molecular Pathology
– Leukaemia Research
– Oncogenic Signalling
– Ovarian Cancer Biomarkers
– STAT Cancer Biology
Research > Centre for Cancer Research > Scientists and Staff > Dr Colin Clyne
Associate Professor Colin Clyne
Research Group Head, Cancer Drug Discovery
Adjunct Senior Lecturer
Department of Biochemistry & Molecular Biology
After graduating from Edinburgh University, UK in 1994 with a PhD in pharmacology, Dr Clyne travelled to the USA, where he completed postdoctoral training with Professor Bill Rainey at the University of Texas Southwestern Medical Centre at Dallas. With a keen interest in gene expression and cancer, he joined Hudson Institute of Medical Research in 1998, where he established the Cancer Drug Discovery Laboratory to drive research into novel endocrine therapeutic targets in breast cancer.
An internationally respected research leader, he has received numerous awards, including an NHMRC Career Development Award, an International Union against Cancer Fellowship, and most recently a prestigious research grant from Worldwide Cancer Research (formerly AICR; Association for International Cancer Research). He has held editorial positions with leading research journals, including Endocrinology and the Journal of Molecular Endocrinology.
Dr Clyne’s current research interests include the pharmacology of nuclear receptors and their co-regulators, and the regulation and action of oestrogen in breast cancer.
Doan TB, Eriksson NA, Graham D, Funder JW, Simpson ER, Kuczek ES, Clyne CD, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL (2014) Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Mol Oncol 8:998-1013.
Lazarus KA, Brown KA, Young MJ, Zhao Z, Coulson RS, Chand AL, Clyne CD (2014) Conditional overexpression of liver receptor homolog-1 in female mouse mammary epithelium results in altered mammary morphogenesis via the induction of TGF-β. Endocrinology 155:1606-1617.
Knower KC, To SQ, Leung YK, Ho SM, Clyne CD (2014) Endocrine disruption of the epigenome: a breast cancer link. Endocr Relat Cancer 21:T33-T55.
Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, Visvader JE, Lindeman GJ, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Graham J, Muscat GE, Clarke CL, Clyne CD (2013) Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat 142:211-223.
Chand AL, Pathirage N, Lazarus K, Chu S, Drummond AE, Fuller PJ, Clyne CD (2013) Liver receptor homologue-1 expression in ovarian epithelial and granulosa cell tumours. Steroids 78:700-706.
To SQ, Knower KC, Clyne CD (2013) NFκB and MAPK signalling pathways mediate TNFα-induced Early Growth Response gene transcription leading to aromatase expression. Biochem Biophys Res Commun 433:96-101.
Lazarus KA, Zhao Z, Knower KC, To SQ, Chand AL, Clyne CD (2013) Oestradiol reduces liver receptor homolog-1 mRNA transcript stability in breast cancer cell lines. Biochem Biophys Res Commun 438:533-539.
To SQ, Simpson ER, Knower KC, Clyne CD (2013) Involvement of early growth response factors in TNFα-induced aromatase expression in breast adipose. Breast Cancer Res Treat 138:193-203.
Muscat GE, Eriksson NA, Byth K, Loi S, Graham D, Jindal S, Davis MJ, Clyne CD, Funder JW, Simpson ER, Ragan MA, Kuczek E, Fuller PJ, Tilley WD, Leedman PJ, Clarke CL (2013) Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol 27:350-365.
Chand AL, Wijayakumara DD, Knower KC, Herridge KA, Howard TL, Lazarus KA, Clyne CD (2012) The orphan nuclear receptor LRH-1 and ERα activate GREB1 expression to induce breast cancer cell proliferation. PLoS One 7:e31593.
Lazarus KA, Wijayakumara D, Chand AL, Simpson ER, Clyne CD (2012) Therapeutic potential of Liver Receptor Homolog-1 modulators. J Steroid Biochem Mol Biol 130:138-146.
Knower KC, To SQ, Takagi K, Miki Y, Sasano H, Simpson ER, Clyne CD (2012) Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat 132:765-771.
Yang J, Chang CY, Safi R, Morgan J, McDonnell DP, Fuller PJ, Clyne CD, Young MJ (2011) Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol Endocrinol 25:32-43.
Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD (2010) Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS One 5:e14389.
Chand AL, Herridge KA, Thompson EW, Clyne CD (2010) The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. Endocr Relat Cancer 17:965-975.